Diagnostic accuracy of 201Thallium-SPECT and 18F-FDG-PET in the clinical assessment of glioma recurrence

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 35, Issue 5, 2008, Pages 966-975

  Gómez Río, Manuel ^a   Rodríguez Fernández, Antonio ^a   Ramos Font, Carlos ^a   López Ramírez, Escarlata ^a   Llamas Elvira, José Manuel ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES   (Spain)

Author keywords

Diagnostic accuracy; FDG PET; Glioma recurrence; Radionecrosis; Tl 201 SPECT

Indexed keywords

CHLORIDE TL 201; FLUORODEOXYGLUCOSE F 18; TRACER; UNCLASSIFIED DRUG; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT; THALLIUM; THALLIUM CHLORIDE;

ADULT; ARTICLE; ASTROCYTOMA; CANCER DIAGNOSIS; CLINICAL ASSESSMENT; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DISEASE SEVERITY; FALSE POSITIVE RESULT; FEMALE; FOLLOW UP; GLIOBLASTOMA; GLIOMA; HISTOPATHOLOGY; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MIXED TUMOR; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; OLIGODENDROGLIOMA; POSITRON EMISSION TOMOGRAPHY; PREVALENCE; PROBABILITY; RECURRENT CANCER; SENSITIVITY AND SPECIFICITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; VISUAL ANALOG SCALE; BRAIN TUMOR; EVALUATION; METHODOLOGY; MIDDLE AGED; REPRODUCIBILITY; SCINTISCANNING; TUMOR RECURRENCE;

BRAIN NEOPLASMS; FEMALE; FLUORODEOXYGLUCOSE F18; GLIOMA; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; THALLIUM; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 42149191875     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-007-0661-5     Document Type: Article

References (38)

1. Hoffman JM. New advances in brain tumour imaging. Curr Opin Oncol. 2001;13:148-53.
2. Cao Y, Sundgren PC, Tsien CI, Chenevert TT, Junck L. Physiologic and metabolic magnetic resonance imaging in gliomas. J Clin Oncol. 2006;24:1228-35.
3. Hollingworth W, Medina LS, Lenkinski RE, Shibata DK, Bernal B, Zurakowski D, et al. A systematic literature review of magnetic resonance spectroscopy for the characterization of brain tumours. AJNR Am J Neuroradiol. 2006;27:1404-11.
4. Ricci PE, Dungan DH. Imaging of low- and intermediate-grade gliomas. Semin Radiat Oncol. 2001;11:103-12.
5. Lang FF, Gilbert MR. Diffusely infiltrative low-grade gliomas in adults. J Clin Oncol. 2006;24:1236-45.
6. Benard F, Romsa J, Hustinx R. Imaging gliomas with positron emission tomography and single-photon emission computed tomography. Semin Nucl Med. 2003;33:148-62.
7. 201Tl uptake in tumours. Eur J Nucl Med Mol Imaging. 1989;15:376-9.
8. Perry JR, Cairncross JG. Glioma therapies: how to tell which work? J Clin Oncol 2003;21:3547-9.
9. Minn H. PET and SPECT in low-grade glioma. Eur J Radiol. 2005;56:171-8.
10. 18F-fluoro-2-deoxyglucose in F98 gliomas in the rat. Eur J Nucl Med Mol Imaging. 2006;33:673-82.
11. 18F-fluorodeoxyglucose PET. AJR Am J Roentgenol. 1994;163:1459-65.
12. Ricci PE, Karis JP, Heiserman JE, Fram EK, Bice AN, Drayer BP. Differentiating recurrent tumour from radiation necrosis: time for re-evaluation of positron emission tomography? AJNR Am J Neuroradiol. 1998;19:407-13.
13. Chao ST, Suh JH, Raja S, Lee SY, Barnett G. The sensitivity and specificity of FDG PET in distinguishing recurrent brain tumor from radionecrosis in patients treated with stereotactic radiosurgery. Int J Cancer. 2001;96:191-7.
14. Jacobs AH, Li H, Winkeler A, Hilker R, Knoess C, Rüger A, et al. PET-based molecular imaging in neuroscience. Eur J Nucl Med Mol Imaging. 2003;30:1051-65.
15. Vos MJ, Berkhof J, Postma TJ, Hoekstra OS, Barkhof F, Heimans JJ. Thallium-201 SPECT: the optimal prediction of response in glioma therapy. Eur J Nucl Med Mol Imaging. 2006;33:222-7.
16. Oriuchi N, Tomiyoshi K, Inoue T, Ahmad K, Sarwar M, Tokunaga M, et al. Independent thallium-201 accumulation and fluorine-18-fluorodeoxyglucose metabolism in glioma. J Nucl Med. 1996;37:457-62.
17. Sasaki M, Kuwabara Y, Yoshida T, Nakagawa M, Fukumura T, Mihara F, et al. A comparative study of thallium-201 SPET, carbon-11 methionine PET and fluorine-18 fluorodeoxyglucose PET for the differentiation of astrocytic tumours. Eur J Nucl Med Mol Imaging. 1998;25:1261-9.
18. Kleihues P, Louis DN, Scheithauer BW, Rorke LB, Reifenberger G, Burger PC, et al. The WHO classification of tumors of the nervous system. J Neuropathol Exp Neruol. 2002;61:215-25.
19. Mc Donald DR, Cascino TL, Schold SC Jr, Cairncross JG. Response criteria for Phase II studies of supratentorial malignant glioma. J Clin Oncol. 1990;8:1277-80.
20. 201Tl-SPECT, FDG-PET and neurostructural imaging in the follow-up of glial brain tumours (Abstract). Eur J Nucl Med Mol Imaging. 2004;31:293-4.
21. 201Tl-SPECT in low-grade gliomas: diagnostic accuracy in differential diagnosis between tumour recurrence and radionecrosis. Eur J Nucl Med Mol Imaging. 2004;31:1237-43.
22. Mettler FA Jr, Guiberteau MJ. Essentials of nuclear medicine imaging. Chapter 4: cerebrovascular system. 5th ed. Philadelphia: Saunders-Elsevier; 2006. p. 53-74.
23. Kim CK, Alavi JB, Alavi A, Reivich M. New grading system of cerebral gliomas using positron emission tomography with F-18 fluorodeoxyglucose. J Neurooncol. 1991;10:85-91.
24. Meyer PT, Schreckenberger M, Spetzger U, Meyer GF, Sabri O, Setani KS, et al. Comparison of visual and ROI-based brain tumor grading using 18F-FDG PET: ROC analyses. Eur J Nucl Med Mol Imaging. 2001;28:165-74.
25. Vos MJ, Tony BN, Hoekstra OS, Postma TJ, Heimans JJ, Hooft L. Systematic review of the diagnostic accuracy of 201Tl single photon emission computed tomography in the detection of recurrent glioma. Nucl Med Commun. 2007;28:431-9.
26. Bryan RN. What's your favourite PET story? Am J Neuroradiol. 1998;19:590.
27. Mineura K, Sasajima T, Kowada M, Ogawa T, Hatazawa J, Shishido F, et al. Perfusion and metabolism in predicting the survival of patients with cerebral gliomas. Cancer. 1994;73:2386-94.
28. Lammertsma AA, Wise RJ, Cox TC, Thomas DG, Jones T. Measurement of blood flow, oxygen utilisation, oxygen extraction ratio, and fractional blood volume in human brain tumours and surrounding oedematous tissue. Br J Radiol. 1985;58:725-34.
29. Chen W, Cloughesy T, Kamdar N, Satyamurthy N, Bergsneider M, Liau L, et al. Imaging proliferation in brain tumours with 18F-FLT PET: comparison with 18F-FDG. J Nucl Med. 2005;46:945-52.
30. Vos MJ, Uitdehaag BM, Barkhof F, Heimans JJ, Baayen HC, Boogerd W, et al. Interobserver variability in the radiological assessment of response to chemotherapy in glioma. Neurology. 2003;60:826-30.
31. Hustinx R, Pourdehnad M, Kaschten B, Alavi A. PET imaging for differentiating recurrent brain tumour from radiation necrosis. Radiol Clin N Am. 2005;43:35-47.
32. Goldman S, Levivier M, Pirotte B, Brucher JM, Wikler D, Damhaut P, et al. Regional glucose metabolism and histopathology of gliomas. A study based on positron emission tomography-guided stereotactic biopsy. Cancer 1996;78:1098-106.
33. Henze M, Mohammed A, Schlemmer HP, Herfarth KK, Hoffner S, Haufe S, et al. PET and SPECT for detection of tumour progression in irradiated low-grade astrocytoma: a receiver-operating-characteristic analysis. J Nucl Med. 2004;45:579-86.
34. Galanis E, Buckner JC. Chemotherapy of brain tumours. Curr Opin Neurol 2000;13:619-25.
35. Jackson RJ, Fuller GN, Abi-Said D, Lang FF, Gokaslan ZL, Shi WM, et al. Limitations of stereotactic biopsy in the initial management of gliomas. Neuro-Oncol. 2001;3:193-200.
36. Siepmann DB, Siegel A, Lewis PJ. Tl-201 SPECT and F-18 FDG PET for assessment of glioma recurrence versus radiation necrosis. Clin Nucl Med. 2005;30:199-200.
37. Belohlávek O, Simonová G, Kantorová I, Novotný J Jr, Liscák R. Brain metastases after stereotactic radiosurgery using the Leksell gamma knife: can FDG PET help to differentiate radionecrosis from tumour progression? Eur J Nucl Med Mol Imaging. 2003;30:96-100.
38. Matheja P, Rickert C, Weckesser M, Palkovic S, Lottgen J, Riemann B, et al. Sequential scintigraphic strategy for the differentiation of brain tumours. Eur J Nucl Med Mol Imaging. 2000;27:550-8.